156 related articles for article (PubMed ID: 11523023)
21. [Anemia in head and neck cancers].
Azria D; Zouhair A; Serre A; Lemanski C; Schneider M; Ozsahin M; Dubois JB; Lartigau E;
Bull Cancer; 2005 May; 92(5):445-51. PubMed ID: 15932808
[TBL] [Abstract][Full Text] [Related]
22. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
23. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
Glaspy J
Semin Hematol; 1997 Jul; 34(3 Suppl 2):20-6. PubMed ID: 9253780
[TBL] [Abstract][Full Text] [Related]
24. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
[TBL] [Abstract][Full Text] [Related]
25. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
26. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
27. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
28. Symptomatology of anemia.
Ludwig H; Strasser K
Semin Oncol; 2001 Apr; 28(2 Suppl 8):7-14. PubMed ID: 11395846
[TBL] [Abstract][Full Text] [Related]
29. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
30. Correction of cancer anemia--impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy.
Henke M
Onkologie; 2001 Oct; 24(5):450-4. PubMed ID: 11694771
[TBL] [Abstract][Full Text] [Related]
31. The impact of hemoglobin levels on treatment outcomes in patients with cancer.
Littlewood TJ
Semin Oncol; 2001 Apr; 28(2 Suppl 8):49-53. PubMed ID: 11395853
[TBL] [Abstract][Full Text] [Related]
32. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
33. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
34. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
Glaspy J; Degos L; Dicato M; Demetri GD
Oncologist; 2002; 7(2):126-35. PubMed ID: 11961196
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of anemia in cancer patients undergoing radiation therapy.
Harrison L; Shasha D; Shiaova L; White C; Ramdeen B; Portenoy R
Semin Oncol; 2001 Apr; 28(2 Suppl 8):54-9. PubMed ID: 11395854
[TBL] [Abstract][Full Text] [Related]
36. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
37. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
Adamson JW; Ludwig H
Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.
Mystakidou K; Kalaidopoulou O; Katsouda E; Parpa E; Kouskouni E; Chondros C; Tsiatas ML; Vlahos L
Anticancer Res; 2005; 25(5):3495-500. PubMed ID: 16101168
[TBL] [Abstract][Full Text] [Related]
39. The effect of Epoetin alfa on quality of life in anemic cancer patients.
Cella D; Bron D
Cancer Pract; 1999; 7(4):177-82. PubMed ID: 10687582
[TBL] [Abstract][Full Text] [Related]
40. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]